The Women's Tennis Association's (WTA) new policy requiring players to undergo sex testing for eligibility has not generated the widespread backlash from top players that some activists had anticipated. World No. 1 Aryna Sabalenka has publicly supported the policy, emphasizing the importance of fairness and biological differences in women's sports. Sabalenka's stance aligns with her previous statements on the matter, noting that men are biologically stronger than women, making competition between the two unfair.
Coco Gauff, the world No. 4, offered a more nuanced response. While she expressed support for the transgender community and acknowledged the complexity of the issue, she did not oppose the WTA's policy. Gauff indicated a "kind of" agreement with protecting fairness in women's sports and recognized biological differences between men and women. Her position, while including qualifications, stopped short of the outright denouncement that activists had hoped for from a prominent progressive athlete.
Jessica Pegula, ranked No. 3 globally and a member of the WTA Players' Council, stated that she has not heard significant complaints from other players regarding the new policy. Pegula, who typically avoids political discussions, noted that players have not widely mentioned or voiced concerns about the testing requirements to her. She suggested that more feedback might emerge once testing commences, but as of now, there have been no major objections from players impacted by the policy. She noted that players deserve to know that their medical information will remain private.
The WTA's updated policy mandates a one-time screening for the SRY gene, typically found on the Y chromosome, using methods such as a cheek swab, blood test, or saliva sample. Players who test negative are generally eligible, though further review may occur if there are doubts about the result. A positive test requires further medical assessment before a player can compete. According to the WTA, the policy is intended to safeguard equal opportunities and fair competition within women's tennis.
This policy requires players to complete a one-time screening for the SRY gene. This test can be done via cheek swab, blood test, or saliva sample. Players who test negative are eligible unless there is a reason to believe the result is inaccurate. A positive test means the player cannot compete while further medical review is conducted. The WTA states the policy is designed to protect fair competition in women's tennis.
Activists had argued that such testing would be invasive and humiliating, serving as a tool in a culture war. However, the reactions from prominent players suggest that the anticipated outrage from within the sport has not materialized, with prominent public responses leaning towards support, qualified acceptance, or a lack of opposition. The current reactions from the top players have presented a challenge to the narrative promoted by activists who believe female athletes are being harmed by rules designed to protect women's competitions. The sentiment within the locker room appears to differ from the outcry expressed by those outside it.